Olaparib
Brand Names: Lynparza
Methodology & AI Transparency ⓘ
Olaparib Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Olaparib (100 mg/1 Tablet, Film Coated and 150 mg/1 Tablet, Film Coated; NDC 0310-0569, 0310-0668) as a oral-route poly(adp-ribose) polymerase inhibitor formulation manufactured/labeled by AstraZeneca Pharmaceuticals LP when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
- 2 Real-world patient consensus: 88% patient "Worth It" rating across 8 anonymous logs for Olaparib (RxNorm RXN-03100569-2404).
- 3 Typical cash cost range: 30-day cash pricing ranges from $90.31 discount cash to $221.26 walk-in retail (NADAC $2.0200/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Olaparib include nausea (9.1%), headache (8.5%), dizziness (5.8%).
Ask our AI Specialists anything about Olaparib
Olaparib Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Olaparib (100 mg/1 Tablet, Film Coated and 150 mg/1 Tablet, Film Coated; NDC 0310-0569, 0310-0668) as a oral-route poly(adp-ribose) polymerase inhibitor formulation manufactured/labeled by AstraZeneca Pharmaceuticals LP when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Olaparib exerts selective poly(adp-ribose) polymerase inhibitor pharmacodynamic activity across 100 mg/1 Tablet, Film Coated and 150 mg/1 Tablet, Film Coated (oral-route route, manufactured/labeled by AstraZeneca Pharmaceuticals LP), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 0310-0569, 0310-0668).
With Biphasic clearance with 5–13 hr terminal t½ under Olaparib maintenance residence kinetics and Systemic oral bioavailability of roughly 59%–71% following first-pass transit bioavailability, Olaparib undergoes hepatic enzymatic processing and renal clearance proportional to creatinine clearance (olaparib) and establishes therapeutic activity over initial pharmacodynamic onset within 1–3 hrs (peak cmax) for olaparib.
Standard adult regimens span 100 mg/1 Tablet, Film Coated, 150 mg/1 Tablet, Film Coated. Prescribers screen specifically against prior anaphylaxis, angioedema, or severe hypersensitivity to olaparib or olaparib excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 olaparib spl, while community micro-logs most frequently note nausea (9.1% of reports), headache (8.5% of reports), fatigue (5.8% of reports).
Avoid overlapping poly(adp-ribose) polymerase inhibitor prescriptions alongside Olaparib to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Olaparib dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Olaparib or Olaparib excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Olaparib SPL
Logged Side-Effect Incidence (8 Reports)
Olaparib Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Olaparib)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Olaparib maintenance single-drug treatment in Chinese patients with Real-world benefits and safety findings in the China SOLO2 cohort support the use of olaparib (300 mg twice daily) as maintenance treatment for Chinese patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation. Asia-Pacific journal of clinical oncology • 2022-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35357078 ↗ |
| Can This Approach Help? Inside the Latest Research on Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit The Geneva HRD test predicts PFS and OS benefit from olaparib + bevacizumab. JCO precision oncology • 2025-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40601896 ↗ |
| New Insights on Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative: What a 302-Participant Study Found Global health status/health-related quality of life increased in all subgroups with olaparib vs decreased/no change with TPC. International journal of cancer • 2023-08-15 • Phase III Randomized Trial | N = 302 | 87/100 | PMID 36971103 ↗ |
Olaparib Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.0200/unit (~$60.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $221.26 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $90.31 / mo | View logs ↓ |
Olaparib Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Olaparib RxNorm Concept ID | RXN-03100569-2404 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.0200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $221.26 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $90.31 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 88.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Olaparib Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Olaparib: FDA labeling (2026-07-01, NDC 0310-0569), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Olaparib community threads and patient logs by age, biological sex, dosage, and treatment duration.